Daiichi Sankyo Company, Limited (DSNKY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous Close | 35.11 |
| Open | 34.84 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 34.53 - 34.84 |
| 52 Week Range | 23.72 - 37.57 |
| Volume | |
| Avg. Volume | 198,820 |
| Market Cap | 67.385B |
| Beta (5Y Monthly) | 0.26 |
| PE Ratio (TTM) | 52.32 |
| EPS (TTM) | 0.66 |
| Earnings Date | Jul 29, 2024 - Aug 02, 2024 |
| Forward Dividend & Yield | 0.24 (0.70%) |
| Ex-Dividend Date | Sept 28, 2023 |
| 1y Target Est | N/A |
Business WireDaiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
BASKING RIDGE, N.J., May 21, 2024--Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
ZacksAstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
Business WireENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
© 2024 Yahoo. All rights reserved.